Axatilimab Shows Efficacy in Recurrent/Refractory GVHD
SAN DIEGO — Axatilimab achieved rapid and durable responses in patients with recurrent/refractory chronic graft-versus-host disease (cGVHD), according to the phase II AGAVE-201 trial. The highest overall response rate (ORR) was observed in patients treated with the lowest dose of axatilimab at 0.3 mg/kg every 2 weeks, with an ORR of 74% (95% CI 63-83) […]